<DOC>
	<DOCNO>NCT00479700</DOCNO>
	<brief_summary>To assess safety tolerability ascend single oral dos SAM-531 healthy subjects.To obtain preliminary pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile SAM-531 , investigational drug , healthy subject evaluate effect high-fat meal PK SAM-531 administer healthy subject .</brief_summary>
	<brief_title>Study Evaluating Safety , Tolerability , Pharmacokinetics , Pharmacodynamics SAM-531 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion 1 . Men woman nonchildbearing potential age 18 45 year 2 . Elderly men woman age 65 year study day 1 . 3 . Body mass index range 18 30 kg/m2 body weight ≥50 kg . Body weight elderly subject must ≥45 kg . Exclusion criteria 1 . Any significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease 2 . Any clinically important deviation normal limit physical examination , vital sign , digital 12lead ECGs , clinical laboratory test result . 3 . Tobacco use consumption caffeinecontaining product ( e.g. , coffee , tea , chocolate , soda ) alcoholic beverage within 48 hour study day 1 , grapefruit grapefruitcontaining product 72 hour study day 1 , end inpatient confinement period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>